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Abstract  
Purpose: Combined information on single nucleotide polymorphisms (SNPs) and 
prostate-specific antigen (PSA) offers opportunities for improving the performance of 
screening by risk stratification. We aimed to predict the risk of prostate cancer (PrCa) 
based on PSA together with SNPs information. 
Materials and Methods: Prospective study of 20,575 men with PSA test and 4,967 men 
with polygenic risk score for PrCa based on 66 SNPs from the Finnish population-based 
screening trial for PrCa and 5,269 samples on seven SNPs from the Finnish PrCa DNA 
study. Bayesian predictive model was built for estimating the risk of PrCa by sequentially 
combining genetic information with PSA in comparison with PSA alone among study 
subjects limited with 4 ng/mL or above.  
Results: The posterior odds for PrCa based on seven SNPs together with the PSA level 
ranged from 3.7 at 4 ng/mL, 14.2 at 6 ng/mL, 40.7 at 8 ng/mL, to 98.2 at 10 ng/mL. The 
area under receiver operating characteristic curve was elevated to 88.8% (95% CI: 
88.6%-89.1%) with PSA in combination with the risk score based on seven SNPs in 
comparison with 70.1% (95% CI: 69.6%-70.7%) with PSA alone. It was further escalated 
to 96.7% (95% CI: 96.5%-96.9%) when all prostate cancer susceptibility polygenes were 
combined.  
Conclusions: Expedient use of multiple genetic variants together with information on 
PSA levels better predicts the risk of PrCa than PSA alone and allows higher PSA cut-
offs. Combined information also provides a basis for risk stratification that can be used 
for optimizing the performance of PrCa screening.  
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Introduction  
  Several international collaborative genome-wide association studies have been 
conducted to identify genetic factors in association with hereditary predisposition to 
prostate cancer (PrCa). A constellation of >120 single-nucleotide polymorphisms (SNPs) 
have been revealed with several located in five chromosomal regions-three at 8q24 and 
one each at 17q12 and 17q24.3.1-5 Although the effect of each of the SNPs on the risk for 
PrCa is small to moderate, a strong cumulative association has been demonstrated by 
using several SNPs in combination. 6 Multiple prostate cancer-specific multigene panels 
have been evaluated for detection of PrCa.7 Use of the major SNPs offers an opportunity 
to identify sub-groups of men with PrCa risk substantially below and above the 
population average. 
  In parallel with these genome-wide studies, the effectiveness of population-based 
screening for PrCA with prostate specific-antigen (PSA) has been intensively researched. 
However, the effectiveness of screening in reducing mortality is still debatable due to 
conflicting results of the two major randomized trials and the balance between benefits 
and harms remains uncertain.8,9 To enhance the efficiency and reduce the harm, i.e. 
overdiagnosis caused by screening, combining genetic information together with PSA 
given age and genetic variant holds promise for more accurate identification of high-risk 
men with potential for large screening benefits.  
  The purpose of this study was to develop a Bayesian algorithm to predict the risk of 
PrCA based on PSA data together with the SNPs identified from the Finnish PrCa DNA 
study and the Finnish population-based screening trial for PrCA in order to compare the 
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performance of the risk prediction for PrCa between PSA alone and PSA with the 
incorporation of information on SNPs.   
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Methods  
Study Subjects and Design  
  To estimate the risk of PrCa based on PSA and selected SNPs, we combined two 
Finnish datasets, one from the population-based randomized screening trial during 1996-
2007 (20,575 men enrolled) and an unselected patient series from Tampere University 
hospital during 1994-2013. The details of study design and preliminary results for the 
former have been published previously10-12 and the mortality results have been published 
also as a part of the ERSPC trial.8 The dataset included DNA samples collected from 
2,959 individuals who participated in the Finnish screening trial (518 prostate cancers 
and 2,441 prostate cancer-free subjects) plus 2310 prostate cancer patients from the 
Tampere University Hospital. It should be noted that information derived from the two 
datasets are complementary with each other as the genetic dataset from the unselected 
patients included wide-scale genetic information but with incomplete PSA data whereas 
the opposite was for the screening trial. Figure 1 gives a summary of the estimates of 
interest, the use of model and distribution, and data sources.  
           In order to do the risk stratification of PrCa, we adopted Bayesian sequential 
design by first classifying PSA into 13 categories with an increment of 0.5 ng/mL in 
study subjects limited with 4 ng/mL following the usual PSA threshold for referral to 
biopsy. Given the risk of PrCa by PSA level, we then added information on SNPs in a 
sequential manner from seven selected SNPs based on unselected patients to 66 SNPs 
based on the screening trial. Receiver operating characteristic (ROC) was used to assess 
the performance of the combined PSA and information on SNPs in comparison with PSA 
alone following the risk predicted by Bayesian algorithm.   
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Genetic polymorphisms  
To incorporate information on SNPs in association with PrCa, we assessed the 
combined effects of seven SNPs, rs4242382, rs6983267, rs1601979, and rs1447295 at 
8q24, rs104865677 at 7p15.2, rs138213197 and rs1859962 at 17q21. The risk allele A of 
rs424238 at 8q24 has been previously reported to be associated with PrCa and aggressive 
PrCa. The risk allele G of rs10486567 at 7p, the intron 2 of the JAZF zinc finger1 gene 
(JAZF1) is commonly seen in Europeans. 13 The association between rs138213197 in 
HOXB13 and the risk of hereditary PrCA has also been addressed, 14 and the effect has 
been shown to be especially strong in the Finnish population.15 With the advent of more 
SNPs in association with PrCa susceptibility, the analysis using polygenetic risk score 
was based on 66 SNPs for a sample of the trial participants, 1093 men with PrCa and 
3874 men without PrCa.16 
 
Statistical Analysis  
   To fit the normal distribution, the PSA concentrations were transformed into 
logarithms.  The distributions of PSA in men with and without PrCa as well as aggressive 
PrCa (Gleason score ≥7) are given in the Appendix Tables 1 and 2. To incorporate 
information on SNPs, we first assessed the effects of each of seven SNPs on PrCa and 
aggressive PrCa by logistic regression analysis. The effects of the combined seven SNP 
on PrCa and aggressive PrCa was evaluated by two ways, treating each SNP as a 
dichotomous variable, and treating seven SNPs as a polygenic risk score. Such a risk-
score-based approach was further applied to 66 SNPs.    
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The optimal cutoff of PSA based on receiver operating characteristics (ROC) curve 
was calculated by the largest value of the formula, Sensitivity + Specificity – 1, from 
each PSA cut-off. The bootstrap method was adopted by sampling individuals with 
replacement from the original sample to validate the prediction model. The sample size 
varied according to the number of events per variable (EPV) from 10 to 80. As the 
genetic variants associated with PCa are heterogeneous, it is necessary to make a 
comparison across different ethnic groups or populations by using the information on the 
proportion of each SNP in population and the effect of each SNP to Pr a risk. We used 
results from the previous Zheng’s study6 for external validation of developed model. The 
details of the algorithm developed by using Bayesian underpinning are given in the 
Appendix. Data analysis was performed with SAS 9.4 and Winbugs software. 
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Results  
 
Estimates of the risk for PrCa (Posterior Odds) by different levels of PSA    
 
Table 1 shows the likelihood ratios for log(PSA) and the SNPs, as well as the 
posterior odds by PSA levels given the prior odds (1: 2.78) for the risk of PrCa for men 
aged 60 years or younger at baseline. Our model was used to discern the PrCa cases from 
4 ng/mL upward given the posterior odds by combining PSA and 7 SNPs, increasing 
from 3.7 (95% CI:1.6-10) at 4 ng/mL of PSA to 98.2 (95% CI:27.3-437.5) at 10 ng/mL of 
PSA. The likelihood ratio based on the presence of the risk alleles of 7 SNPs was 2.8 
considering the weighted distribution (the proportion of each SNP in population) 
contributed from each SNP (see the footnote of Table 1). The frequencies of these 7 
SNPs in patients and controls are listed in Appendix Tables 2-1 to 2-7. The 
corresponding posterior odds for PrCa based on risk-score model with 7 SNPs as well as 
all susceptibility polygenes are presented in Appendix Tables 3-1 and 3-2. The posterior 
probability of PrCA by age and PSA level taking 7 SNPs into account was simulated and 
the results are shown in Figure 2.  
 
ROC curves limited to men with PSA ≥ 4 ng/mL  
Adding SNP information to this risk group substantially enhanced the 
performance of risk prediction for PrCA as the area under curve (AUC) from 70.1% 
based on PSA only to 95.8% based on PSA combined with 7 SNPs when each of SNP 
was treated as a binary variable (Figure 3).  
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Figure 4 (A) shows the corresponding figure was 88.8% with 7 SNPs and was 
elevated to 96.7% when 66 SNPs were considered on the basis of the risk-score-based 
approach. It is very interesting to see PSA combined with 66 SNPs was not able to 
enhance the performance of risk prediction for aggressive PrCA as good as PSA 
combined with 7 SNPs (Figure 4(B)). The AUC increased from 77.0% based on PSA 
alone to 83.8% based on PSA combined with 7 SNPs whereas 80.6% of the AUC was 
noted when PSA was combined with 66 SNPs. 
 
External Validation  
The proposed predictive model was further extended to incorporate 5 SNPs from the 
Zheng’s study.6 Considering the 5 SNPs, the odds of PrCa was 2.4 at 4 ng/mL compared 
with 2 at 0.6 ng/mL (Table 2). The optimal cutoff was 9.9 ng/mL when using PSA plus 5 
SNPs. The corresponding AUC was 86.8% (95% CI: 86.6%-87.0%). 
The external validation based on four common SNPs (rs1859962, rs16901979, 
rs6983267, and rs1447295) from the Finnish and Zheng’s studies was also conducted. 
The predicted ROC curve was built by applying the regression coefficients of 4 SNPs 
obtained from the Zheng’s study to the empirical Finnish PSA data. The comparison 
between the externally predicted ROC and the observed ROC of the Finnish PSA data is 
shown in Figure 5. We found that AUC of 81.7% (95% CI: 81.5%-82.0%) in the Zheng’s 
study was slightly lower than the 85.3% (95% CI: 85.1%-85.5%) in Finnish data 
(P<0.0001). The statistical significant difference suggests the results are not compatible 
even if the difference in the ROC values was not substantial.   
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Discussion  
 
 Using a novel clinical prediction algorithm with Bayesian underpinning that 
provides a feasible approach for the risk stratification of PrCa by combing information on 
PSA multiple genetic variants identified from genome-wide studies, we demonstrate here 
that adding available SNPs information to subjects with PSA > 4 ng/mL increased 
predictive ability of AUC substantially (by 25 percentage points) in our analysis. The 
enhanced predictive ability resulting from additional information on SNPs noted in the 
current study was supported by the recent finding that of 7.7-fold difference between the 
top and bottom 10 percent of polygenic risk score using 147 prostate cancer-susceptibility 
variants.17 This finding leads to the following three merits for PSA screening. Firstly, the 
combined use of information on PSA and the SNPs may reduce false negative cases 
missed at PSA screen (such as interval cancer), as some men with low PSA levels may 
nevertheless have an increased risk of PrCA if they carry one or more high-risk alleles. 
The posterior odds was 4-fold higher than the prior based on PSA alone at 4 ng/ml if all 7 
risk SNPs were present. Second, so doing may also reduce false positive results. The 
optimal cut-off was raised from 9.1 to 10.7 when information on the 7 SNPs is added, 
which is likely to reduce the frequency of screen-positive findings (Among men with ≥4 
ng/mL, 17.5 % of men had PSA>9.1 ng/mL in our screening data). Third, the large 
contrast in PrCa risk between high and low-risk groups provides opportunities for 
individually tailored screening strategy including the adoption of screening tool, inter-
screening interval, and age to begin with screen. The higher the risk predicted by the 
proposed model, the more advanced detection method, the shorter inter-screening 
interval, and the earlier age of commencing screening should be considered12. 
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There are four concerns that should be addressed here from both methodological 
and application viewpoints. A key methodological concern is the assumption that the 
SNPs are independent of PSA level, which remains imperfectly verified. It could be 
debated whether such an assumption is reasonable. A previous study demonstrated that 
the five PrCA associated SNPs were independent of PSA levels6. There is no significant 
association between SNPs and PSA concentration in patient samples18,19. Accordingly, 
the joint effect of PSA and these seven SNPs can be easily decomposed into the product 
of their independent effects. Although this assumption is supported by Zheng et al., it 
should be empirically verified before applying our PrCa risk stratification algorithm for 
screening. It should be noted that AUC decreased from 95.8% in independent effect 
model treating the effect of each SNP as a binary variable to 88.8% in risk-score-based 
model for selected 7 SNPs. The risk-score-based model can capture the correlations 
within selected SNPs. Unfortunately, the risk-based approach cannot be validated by 
Zheng’s study as risk score was not available from their study. 
  As far as the consistency of results across studies is concerned, the performance of 
our results were compatible but slightly higher than those previous findings that 
predicting the risk for PrCa with PSA limited to PSA≥4 ng/mL20-24 with the ranges of 
AUCs from 61 to 71%. The higher AUC in ROC analysis might be arguable with 
whether the predictive model is reliable in terms of sample size. To relieve this concern, 
the internal-validation by bootstrap method was therefore performed. With 500 bootstrap 
replications, the mean AUCs were ranged between 69.10% and 68.01% for EPV from 10 
to 80, respectively. The estimated optimism was 0.06% (= 69.10%-68.04% (full samples)) 
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for EPV=10, which shows good discrimination. With large sample size (EPV=40 or 80), 
a reduction in optimism but not a substantial difference was found, suggesting the 
reliability of the prediction model.  
Another concern is the variation in genetic risk prediction across populations, i.e. 
population stratification. The genetic determinants of PrCa risk from different 
populations are not highly consistent, suggesting that the genetic factors underlying 
hereditary susceptibility may vary between populations. The validation was not well 
fitted in our analysis of external validation. This suggests that different SNPs will need to 
be incorporated in different populations. It is still unclear to what extent the proposed 
model can be applied to populations other than where it has been developed (possible 
overfitting). The contribution of additional SNPs depends on their frequency, effect size 
and independence of the already incorporated SNPs. However, we found that PSA 
combined with risk-score-based approach based on 7 SNPs out-performed PSA combined 
with polygenetic risk score based on 66 SNPs for risk prediction of aggressive tumor. 
Such a finding for aggressive prediction was not identical to that for the risk of PrCA. 
This suggests that the majority of 59 additional SNPs may not be predictive of aggressive 
PrCa in comparison with seven SNPs. The explanation is that seven SNPs may 
predispose people with family history of PrCa to aggressive PrCa but other 59 SNPs may 
not have such a predisposition. This postulate was supported by the recent finding from 
Chen et al study 25 that the incorporation of GRS to family history can improve the 
detection of aggressive PrCa. However, this deserves a further research to verify.  
Finally, although our risk stratification by combing PSA and SNP information can 
provide an efficient personalized preventive strategy by reducing false negative results 
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and also false positive findings, the incorporation of genetic information may involve 
substantial costs. It is of great concern over whether improved performance in early 
detection can outweigh the cost incurred by the genetic testing, particularly when the unit 
cost of such genetic testing at population level would be reduced due to an economic 
scale.  However, this requires a formal cost-effectiveness analysis for the evaluation of 
the net balance between costs from genetic testing and benefits from early detection.    
         In conclusion, the expedient use of multiple genetic variants in seven chromosomal 
regions associated with PrCa risk together with information on PSA through a Bayesian 
reasoning algorithm improves risk stratification, which could provide the basis for risk-
adapted PrCa screening to maximize its benefits and minimize the harms.  
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FIGURE LEGENDS 
Figure 1. Summary of the estimates of interest, the use of model and distribution, and 
data sources. 
Figure 2. Posterior odds of prostate cancer by age with or without considering seven 
SNPs Finnish Study. 
Figure 3. Receiver operating characteristic curves for prostate cancer based on PSA alone 
and PSA plus genetic data (seven SNPs).  
Figure 4. Receiver operating characteristic curves for prostate cancer (A) and aggressive 
prostate cancer (B) based on PSA alone, PSA plus risk socre with seven SNPs, and PSA 
plus polygenetic risk score. 
Figure 5. Receiver operating characteristic curves for external validation based on four 
common SNPs(rs1859962, rs16901979, rs6983267, and rs144729
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Table 1. Posterior odds of prostate cancer by PSA level based on seven SNPs, the Finnish prostate cancer screening trial 
PSA 
Level 
Men younger 60 years Men aged 63-71 years 
P(PSA|D)/P(PSA| ) 
Likelihood Ratio 
given PSA 
(A) 
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, 
, … , 
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SNP-specific risk 
(B) 
Posterior Odds by combing PSA 
and 7 SNPs 
(C) 
P(PSA|D)/P(PSA| ) 
Likelihood Ratio 
given PSA 
(A) 

, 
, … , 

|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, 
, … , 

|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SNP-specific risk 
(B) 
Posterior Odds by combing 
PSA and 7 SNPs 
(C) 
Estimate Estimate Estimate 95%CI Estimate Estimate  Estimate  95%CI 
4.0 3.8 2.8 3.7 (1.6-10) 1.39 2.8 1.3 (0.6-3) 
4.5 5.5 2.8 5.4 (2.2-15.3) 1.86 2.8 1.8 (0.8-4.2) 
5.0 7.7 2.8 7.6 (3-23.3) 2.42 2.8 2.3 (1.1-5.6) 
5.5 10.7 2.8 10.5 (3.9-33.6) 3.10 2.8 2.9 (1.3-7.5) 
6.0 14.5 2.8 14.2 (5.2-47.5) 3.89 2.8 3.7 (1.6-10) 
6.5 19.3 2.8 18.8 (6.5-65.7) 4.82 2.8 4.6 (2-12.7) 
7.0 25.3 2.8 24.7 (8.4-89.1) 5.90 2.8 5.6 (2.4-16) 
7.5 32.7 2.8 31.9 (10.3-122.6) 7.16 2.8 6.8 (2.8-20.1) 
8.0 41.8 2.8 40.7 (12.9-157.4) 8.60 2.8 8.2 (3.2-24.7) 
8.5 52.9 2.8 51.5 (15.6-207) 10.25 2.8 9.7 (3.8-30.2) 
9.0 66.1 2.8 64.9 (18.9-267) 12.14 2.8 11.5 (4.4-36.7) 
9.5 81.9 2.8 79.8 (22.6-348.4) 14.27 2.8 13.6 (5-44.5) 
10.0 100.8 2.8 98.2 (27.28-437.5) 16.64 2.8 15.7 (5.7-54) 
# Considering seven SNPs (rs4242382 & rs10486567 & rs16901979 & rs6983267& rs138213197 & rs1447295 & rs1859962) from the Finnish DNA study 
The likelihood ratios: 1.88 (95% CI:1.42-2.49) for rs4242382, 1.68 (95% CI:1.35-2.09) for rs10486567, 1.45 (95% CI:1.18-1.77) for rs1601979, 1.54 (95% 
CI:1.36-1.74) for rs6983267, 8.98 (95% CI:5.51-14.65) for rs138213197, 1.93 (95% CI:1.46-2.56) for rs1447295, and 1.42 (95% CI:1.25-1.61) for rs1859962, 

,
,…,
|

,
,…,
|
:exp (0.0438*log(1.88) +0.933*log(1.68) +0.0818*log(1.45) +0.285*log(1.54) +0.0367*log(8.98) +0.0441*log(1.93) 
+0.7558*log(1.42)) =2.8 
C = 	


×  × 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Table 2. Posterior odds of prostate cancer by PSA level based on five SNPs data from Zheng’s study 
PSA 
Level 
Men younger 60 years Men aged 63-71 years 
P(PSA|D)/P(PSA| ) 
Likelihood Ratio 
given PSA 
(A) 

, 
, … , 

|

, 
, … , 

|
 
SNP-specific risk 
(B) 
Posterior Odds by combing PSA 
and 5 SNPs# 
(C) 
P(PSA|D)/P(PSA| ) 
Likelihood Ratio 
given PSA 
(A) 

, 
, … , 

|

, 
, … , 

|
 
SNP-specific 
risk 
(B) 
Posterior Odds by combing PSA 
and 5 SNPs# 
(C) 
Estimate Estimate Estimate  95%CI Estimate Estimate  Estimate  95%CI 
4.0 3.8 1.7 2.3 (1-6.1) 1.39 1.7 0.8 (0.4-1.8) 
4.5 5.5 1.7 3.4 (1.4-9.5) 1.86 1.7 1.1 (0.6-2.6) 
5.0 7.7 1.7 4.8 (1.9-14.4) 2.42 1.7 1.5 (0.7-3.5) 
5.5 10.7 1.7 6.7 (2.6-21) 3.10 1.7 1.9 (0.9-4.6) 
6.0 14.5 1.7 9.0 (3.4-29) 3.89 1.7 2.3 (1.1-6.1) 
6.5 19.3 1.7 11.9 (4.3-41.4) 4.82 1.7 2.9 (1.3-7.8) 
7.0 25.3 1.7 15.7 (5.4-55.8) 5.90 1.7 3.5 (1.5-9.9) 
7.5 32.7 1.7 20.3 (6.7-75.5) 7.16 1.7 4.3 (1.8-12.5) 
8.0 41.8 1.7 26.0 (8.3-100.2) 8.60 1.7 5.2 (2.1-15.4) 
8.5 52.9 1.7 32.7 (10.1-129.9) 10.25 1.7 6.2 (2.5-18.7) 
9.0 66.1 1.7 40.8 (12.3-168.2) 12.14 1.7 7.3 (2.8-23.1) 
9.5 81.9 1.7 50.7 (14.7-217.1) 14.27 1.7 8.6 (3.3-27.5) 
10.0 100.8 1.7 62.4 (17.74-271) 16.64 1.7 10.0 (3.7-33.1) 
# Considering five SNPs (rs4430796, rs1859962, rs16901979, rs6983267, and rs1447295) from Zheng’s study 

,
,…,
|

,
,…,
|
:exp(0.56*log(1.38)+0.5*log(1.28)+0.03*log(1.53)+0.51*log(1.37)+0.14*log(1.22)) =1.7 
C = 	


×  × 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Abbreviations 
 
AUC Area Under Curve 
PSA  Prostate-Specific Antigen 
PrCa Prostate Cancer 
ROC Receiver Operating Characteristic 
SNPs Single Nucleotide Polymorphisms  
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Prediction of the risk of PrCa with SNPs and PSA levels by using Bayesian clinical 
reasoning       
We adopted a Bayesian clinical reasoning to estimate PSA- and SNP-based posterior odds 
for PrCa by updating the baseline risk of PrCa (prior) with the likelihood ratios between PrCa 
positive and negative men formed by the two corresponding distributions of PSA and the other 
likelihood ratio based on SNPs contribution, which is equivalent to the ratio of sensitivity to false 
positive, yielding the ROC curve. The posterior odds of developing prostate cancer given a 
specific PSA level and the SNPs of interests by the Bayesian algorithm considering different 
scenarios are derived as follows:  
(1) With seven SNPs  
(|, 
, … , , 	)(|, 
, … , , 	)  
= ()() × (	|, 
, 
, … , )(	|, , 
, … , ) ×
(, 
, … , |)(, 
, … , |) 
 
, where D represents the event of prostate cancer, and  is the complement of D (non-
disease). P(D) is prior probability of prostate cancer and P( ) is prior probability of being free 
of prostate cancer. 
Assume PSA level is the conditionally independent of SNP once the disease status is 
determined. The formula can be simplified as (|)( |) 
Let PSAD and PSA  denote PSA in men with and without prostate cancer. Both follow the two 
normal distributions, indicated by N( , 
) and N( , 
); the likelihood ratio then becomes 
(	|,,,…,)(	|,,,…,)=   × !"# $− 
 &'(	)  * − '(	)  *+, 
 
  : the average estimate of PSA for prostate cancer cases   : standard deviation of PSA for prostate cancer cases  
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  : average PSA for prostate cancer free men 
  : standard deviation of PSA for prostate cancer free men  
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Appendix Table 1-1: The distribution of PSA with log transformation among men with and without prostate cancer in the Finnish 
prostate cancer screening trial 
Age 
Free of Prostate Cancer 
 
Prostate Cancer 
 
N log(PSA), Mean(SD) N 
log(PSA), 
Mean(SD) p-Value
*
 
Age 55-59 399 1.742(0.325) 227 2.156 (0.705) <0.0001 
      
Age 63-71 719 1.801(0.346) 388 2.251(0.801) <0.0001 
Overall 1118 1.780(0.340) 615 2.216(0.768) <0.0001 
* Adjusting for age   
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Appendix Table 1-2: The distribution of PSA with log transformation among men with and without aggressive prostate cancer in the 
Finnish prostate cancer screening trial 
Age 
Free of Aggressive 
Prostate Cancer 
 
Aggressive Prostate Cancer 
 
N log(PSA), Mean(SD) N 
log(PSA), 
Mean(SD) p-Value
*
 
Age 55-59 590 1.842(0.455) 36 2.718 (0.941) <0.0001 
      
Age 63-71 1025 1.892(0.478) 82 2.786(1.055) <0.0001 
Overall 1615 1.874(0.470) 118 2.765(1.018) <0.0001 
* Adjusting for age   
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Appendix Table 2-1: The risk of prostate cancer for the SNP of rs4242382 from Finnish population  
 
 Genotype  OR  
AA vs. GA/GG P 
 GG GA AA 
Non-prostate 
Cancer 1721(70.5%) 646(26.5%) 74(3%) 1.88(1.42-2.49) <0.0001 Prostate 
Cancer   1729(61.1%) 942(33.3%) 157(5.6%) 
 
Appendix Table 2-2: The risk of prostate cancer for the SNP of rs10486567 from Finnish population 
 
 Genotype  OR  
GG/GA vs. AA P 
 GG GA AA 
Non-prostate 
Cancer 1254(51.4%) 981(40.2%) 206(8.4%) 1.68(1.35-2.09) <0.0001 Prostate 
Cancer   1685(59.6%) 996(35.2%) 147(5.2%) 
 
Appendix Table 2-3: The risk of prostate cancer for the SNP of rs16901979 from Finnish population 
 
 Genotype  OR  
AA/AC vs. CC P 
 AA AC CC 
Non-
prostate 
Cancer 
4(0.2%) 160(6.6%) 2277(93.3%) 
1.45(1.18-1.77) 0.0003 
Prostate 
Cancer   6(0.2%) 261(9.2%) 2561(90.6%) 
Appendix Table 2-4: The risk of prostate cancer for the SNP of rs6983267 from Finnish population 
 
 Genotype  OR  
AA/AC vs. CC P 
 AA AC CC 
Non-prostate 
Cancer 625(25.6%) 1233(50.5%) 583(23.9%) 1.54(1.36-1.74) <0.0001 Prostate 
Cancer   530(18.7%) 1377(48.7%) 921(32.6%) 
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Appendix Table 2-5: The risk of prostate cancer for the SNP of rs138213197 from Finnish population 
 
 Genotype  OR  
TT/CT vs. CC P 
 CC CT TT 
Non-prostate 
Cancer 2418(99.3%) 18(0.7%) 0(0%) 8.98(5.51-
14.65) <0.0001 Prostate 
Cancer   2572(93.7%) 171(6.2%) 1(0%) 
 
Appendix Table 2-6: The risk of prostate cancer for the SNP of rs1447295 from Finnish population 
 
 Genotype  OR  
AA vs. AC/CC P 
 AA AC CC 
Non-prostate 
Cancer 73(3%) 710(29.2%) 1652(67.8%) 1.93(1.46-2.56) <0.0001 Prostate 
Cancer   159(5.6%) 990(35.1%) 1673(59.3%) 
 
Appendix Table 2-7: The risk of prostate cancer for the SNP of rs1859962 from Finnish population 
 
 Genotype  OR  
AA/AC vs. CC P 
 AA AC CC 
Non-
prostate 
Cancer 
681(27.9%) 1193(48.9%) 566(23.2%) 
1.42(1.25-1.61) <0.0001 
Prostate 
Cancer   604(21.4%) 1421(50.4%) 797(28.2%) 
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Appendix Table 3-1. Posterior odds of prostate cancer by PSA level based on risk score with seven SNPs, the Finnish prostate cancer 
screening trial 
PSA 
Level 
Men younger 60 years Men aged 63-71 years 
P(PSA|D)/P(PSA| ) 
Likelihood Ratio 
given PSA 
(A) 

, 
, … , 

|

, 
, … , 

|
 
SNP-specific risk 
(B) 
Posterior Odds by combing PSA 
and 7 SNPs# 
(C) 
P(PSA|D)/P(PSA| ) 
Likelihood Ratio 
given PSA 
(A) 

, 
, … , 

|

, 
, … , 

|
 
SNP-specific risk 
(B) 
Posterior Odds by combing 
PSA and 7 SNPs# 
(C) 
Estimate Estimate Estimate 95%CI Estimate Estimate  Estimate  95%CI 
4.0 3.8 1.567 2.1 (0.9-5.6) 1.4 1.567 0.8 (0.4-1.7) 
4.5 5.5 1.567 3.1 (1.3-8.7) 1.9 1.567 1.0 (0.5-2.3) 
5.0 7.7 1.567 4.4 (1.8-13.2) 2.4 1.567 1.3 (0.6-3.2) 
5.5 10.7 1.567 6.1 (2.3-19.2) 3.1 1.567 1.7 (0.8-4.2) 
6.0 14.5 1.567 8.3 (3.1-26.5) 3.9 1.567 2.1 (1-5.5) 
6.5 19.3 1.567 10.9 (3.9-37.8) 4.8 1.567 2.6 (1.2-7.1) 
7.0 25.3 1.567 14.4 (4.9-51) 5.9 1.567 3.2 (1.4-9) 
7.5 32.7 1.567 18.5 (6.1-69) 7.2 1.567 3.9 (1.7-11.4) 
8.0 41.8 1.567 23.8 (7.6-91.7) 8.6 1.567 4.7 (2-14.1) 
8.5 52.9 1.567 29.9 (9.3-118.9) 10.3 1.567 5.7 (2.3-17.1) 
9.0 66.1 1.567 37.3 (11.3-153.9) 12.1 1.567 6.7 (2.6-21.1) 
9.5 81.9 1.567 46.4 (13.5-198.6) 14.3 1.567 7.8 (3-25.1) 
10.0 100.8 1.567 57.1 (16.2-248) 16.6 1.567 9.1 (3.4-30.3) 
# Considering seven SNPs (rs4242382 & rs10486567 & rs16901979 & rs6983267& rs138213197 & rs1447295 & rs1859962) from the Finnish DNA study 

,
,…,
|

,
,…,
|
: exp(0.4492) =1.567 
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Appendix Table 3-2. Posterior odds of prostate cancer by PSA level based on Polygenetic Risk, the Finnish prostate cancer screening 
trial 
PSA 
Level 
Men younger 60 years Men aged 63-71 years 
P(PSA|D)/P(PSA| ) 
Likelihood Ratio 
given PSA 

, 
, … , 

|

, 
, … , 

|
 
Polygenetic Risk 
Posterior Odds by combing PSA 
and Polygenetic Risk Score 
P(PSA|D)/P(PSA| ) 
Likelihood Ratio 
given PSA 

, 
, … , 

|

, 
, … , 

|
 
Polygenetic Risk 
Posterior Odds by combing 
PSA and Polygenetic Risk 
Score 
Estimate Estimate Estimate 95%CI Estimate Estimate  Estimate  95%CI 
4.0 3.8 3.12 4.2 (1.9-11.2) 1.39 3.12 1.5 (0.8-3.4) 
4.5 5.5 3.12 6.2 (2.6-17.3) 1.86 3.12 2.0 (1-4.7) 
5.0 7.7 3.12 8.8 (3.5-26.3) 2.42 3.12 2.6 (1.3-6.4) 
5.5 10.7 3.12 12.1 (4.6-38.2) 3.10 3.12 3.4 (1.6-8.4) 
6.0 14.5 3.12 16.4 (6.1-52.7) 3.89 3.12 4.2 (1.9-11) 
6.5 19.3 3.12 21.7 (7.8-75.3) 4.82 3.12 5.3 (2.3-14.2) 
7.0 25.3 3.12 28.6 (9.8-101.5) 5.90 3.12 6.5 (2.8-18) 
7.5 32.7 3.12 36.9 (12.2-137.4) 7.16 3.12 7.8 (3.3-22.7) 
8.0 41.8 3.12 47.4 (15.2-182.5) 8.60 3.12 9.4 (3.9-28.1) 
8.5 52.9 3.12 59.5 (18.4-236.5) 10.25 3.12 11.3 (4.5-34) 
9.0 66.1 3.12 74.3 (22.4-306.2) 12.14 3.12 13.3 (5.2-42) 
9.5 81.9 3.12 92.3 (26.8-395.2) 14.27 3.12 15.6 (6-50) 
10.0 100.8 3.12 113.6 (32.3-493.4) 16.64 3.12 18.1 (6.8-60.3) 
The likelihood ratios for polygenetic risk score: 3.12(2.78-3.50) 

,
,…,
|

,
,…,
|
:exp (log(1.13) =3.12 
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Appendix Figure 1: Receive Operating Characteristic Curves for Prostate Cancer using 
traditional logistic regression analysis.  
 
PSA ≥4, AUC : 0.68 (0.65-0.71) 
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